stockportfolio.pro
Stocks / TBPH vs XNCR
TBPH vs XNCR
Theravance Biopharma, Inc. and Xencor, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Theravance Biopharma, Inc. (TBPH) | Xencor, Inc. (XNCR) | |
|---|---|---|
| Market cap | $0.8B | $0.9B |
| Revenue (latest FY) | $107.46M | $125.58M |
| Net income (latest FY) | $105.89M | $-91.92M |
| Revenue growth (5y CAGR) | 8.4% | 0.5% |
| Net margin | 98.5% | -73.2% |
| Return on equity | 35.7% | -14.5% |
| P/E ratio | 7.4 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 3 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open TBPH — free Open XNCR — freeFrequently asked questions
Which is bigger, TBPH or XNCR?
Xencor, Inc. is larger by market capitalization — $0.9B versus $0.8B.
Which grows faster, TBPH or XNCR?
Over the last five fiscal years, Theravance Biopharma, Inc. grew revenue faster — 8.4%/yr versus 0.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.